| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
Voxzogo is owned by Biomarin Pharm.
Voxzogo contains Vosoritide.
Voxzogo has a total of 4 drug patents out of which 0 drug patents have expired.
Voxzogo was authorised for market use on 19 November, 2021.
Voxzogo is available in powder;subcutaneous dosage forms.
Voxzogo can be used as use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.
Drug patent challenges can be filed against Voxzogo from 2025-11-19.
The generics of Voxzogo are possible to be released after 01 August, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity (ODE) | Nov 19, 2028 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 2025-11-19
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
VOXZOGO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic